Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk-benefit evaluation is essential to guide optimal treatment decisions.
Authors
- Guido Kobbe (ORCID: https://orcid.org/0000-0002-9745-8813)
- Nicolaus Martin Kröger (ORCID: https://orcid.org/0000-0001-5103-9966)
- Ariane Boumendil (ORCID: https://orcid.org/0000-0002-2552-0542)
- Dominic Edelmann (ORCID: https://orcid.org/0000-0001-7467-6343)
- Rubina Siddiqi (ORCID: https://orcid.org/0000-0003-0244-1531)
- Dietrich W. Beelen (ORCID: https://orcid.org/0000-0001-5050-220X)
- Didier Blaise (ORCID: https://orcid.org/0000-0002-5684-9447)
- Ioana Kloos
- Yasmina Serroukh (ORCID: https://orcid.org/0000-0001-8751-5725)
- Jenny Byrne
- Maija Itälä‐Remes (ORCID: https://orcid.org/0000-0001-5844-1632)
- Tom van Meerten (ORCID: https://orcid.org/0000-0002-5581-6950)
- Nora Liebers
- Sascha Dietrich (ORCID: https://orcid.org/0000-0002-0648-1832)
- Jean‐Jacques Tudesq (ORCID: https://orcid.org/0000-0003-4879-8106)
- Carlos Solano (ORCID: https://orcid.org/0000-0003-3702-0817)
- Anna Sureda (ORCID: https://orcid.org/0000-0002-1238-6970)
- Peter Dreger (ORCID: https://orcid.org/0000-0002-7429-8570)
- Elande Baro
- Anna Ossami Saidy
- Ana Nunes
- Bertram Glaß (ORCID: https://orcid.org/0009-0000-0816-688X)
- Susanne Schmidt
- Goda Choi (ORCID: https://orcid.org/0000-0003-2348-5947)
- Dan Zheng
- Ben‐Niklas Baermann (ORCID: https://orcid.org/0009-0000-1699-9478)
- Hervé Finel
Institutions
- University Medical Center Groningen (NL)
- University of Nottingham (GB)
- Universität Hamburg (DE)
- Universitat de València (ES)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Turku University Hospital (FI)
- University Hospital Heidelberg (DE)
- Sorbonne Université (FR)
- MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE)
- Düsseldorf University Hospital (DE)
- Hospital Clínico Universitario de Valencia (ES)
- Integrated Oncology (United States) (US)
- Hôpital Saint-Antoine (FR)
- Institut Català d'Oncologia (ES)
- University Medical Center Hamburg-Eppendorf (DE)
- National Center for Tumor Diseases (DE)
- Essen University Hospital (DE)
- Aadi (United States) (US)
- Hôpital Lapeyronie (FR)
- Erasmus MC Cancer Institute (NL)
- Institut Paoli-Calmettes (FR)
- Helios Hospital Berlin-Buch (DE)
- European Society for Blood and Marrow Transplantation (FR)
- Heinrich Heine University Düsseldorf (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Blood Cancer Discovery
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1158/2643-3230.bcd-24-0178
- Citations
- 6
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.83
Funders
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung